Researchers at Memorial Sloan-Kettering Cancer Center and Vion will study the use of TAPET bacterial vector technology for tumor diagnostic imaging in preclinical animal models. The goal is to define molecular signatures that result in preferential accumulation of TAPET bacteria in tumors, enabling more effective diagnosis.
TAPET technology, a genetically altered Salmonella bacteria, shows improved antitumor activity when combined with radiation therapy. The NIH/NCI-funded SBIR grant aims to confirm this benefit in animal studies and develop a 'triple play' treatment for solid tumors.
The NIH granted Vion Pharmaceuticals a two-year, $750,000 Small Business Innovation and Research (SBIR) grant to enhance the anti-tumor efficacy of its TAPET bacterial vector. The goal is to deliver potent anti-cancer agents directly at the tumor site, leveraging TAPET's preferential replication in tumors.
Researchers at Vion Pharmaceuticals have developed a novel gene-based anti-cancer drug delivery system using Salmonella bacteria. The TAPET technology has shown complete tumor regression in mice and high safety profiles, with potential applications for treating various types of cancer.